QuantumScape released its Q3 2024 business report this afternoon, and the biggest news is an update regarding the progress of its solid-state battery development and production. According to the ...
The need for cell therapy production improvements is acute, which in turn lends support to approaches like Cellares’ and Ori’s, Tracxn said in its report ...
When most people think of cancer care, they rarely associate it with what goes on behind the scenes to create life-saving treatments. For starters, developing cell and gene therapies is pricey, and ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
Ottawa, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The global cell and gene therapy manufacturing market size was calculated at USD 21.15 billion in 2025 and is expected to reach around USD 215.18 billion by ...
To qualify for advanced manufacturing technology designation from the FDA, a company must present a manufacturing approach that incorporates a new technology or uses an established technology in a ...
A new approach to manufacturing cells that secrete and deliver therapies to specific parts of the body has taken a big step toward one day repairing joints and damage after heart attacks, countering ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results